189 related articles for article (PubMed ID: 36267741)
1. Efficacy and safety of apatinib in patients with untreated or chemotherapy-refractory soft tissue sarcoma: a multicenter, phase 2 trial.
Yu W; Zhang H; Chen J; Zhang X; Chen Y; Qu G; Huang G; Zhou Y; Ye T; Fan Z; Yao Y
Ann Transl Med; 2022 Sep; 10(18):981. PubMed ID: 36267741
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of apatinib in advanced refractory soft tissue sarcoma and association with histologic subtypes: a multicenter retrospective study.
Wang X; Wang J; Sun B; Sun Y; Liu N; Niu X; Li C; Li L; Zhang Q; Hao J; Wang X
Ann Transl Med; 2022 Sep; 10(18):961. PubMed ID: 36267758
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of the VEGFR2 inhibitor Apatinib for metastatic soft tissue sarcoma: Chinese cohort data from NCT03121846.
Liu X; Xu J; Li F; Liao Z; Ren Z; Zhu L; Shi Y; Zhao G; Bai X; Zhao J; Xing R; Teng S; Yang Y; Yang J
Biomed Pharmacother; 2020 Feb; 122():109587. PubMed ID: 31786466
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of apatinib in patients with recurrent uterine malignancy: a prospective, single-center, single-arm, phase 2 study.
Ren Y; Wang T; Cheng X; Ke G; Huang Y; Yang H; Huang X; Tian W; Wang H
Ann Transl Med; 2023 Jan; 11(2):106. PubMed ID: 36819505
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of apatinib as second or later-line therapy in extensive-stage small cell lung cancer: a prospective, exploratory, single-arm, multi-center clinical trial.
Liu Q; Xu JY; Xu YH; Chen M; Deng LC; Wu JP; Zhou T; Zhang LQ; Tan J; Pu XX; Shang YL; Hua J; Li YQ; Cai W; Gu YL; Peng XC; Chan PC; Jabbour SK; Nam HS; Hua D
Transl Lung Cancer Res; 2022 May; 11(5):832-844. PubMed ID: 35693282
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of second-line therapy with apatinib combined with chemotherapy as second-line therapy in advanced gastric cancer: a single-arm, open-label, prospective, multicenter study.
Zhang Y; Xu J; Wang Q; Ling G; Mao Y; Cai M; Yang Y; Mei J; Han Z; Feng J; Wu Y; Shi L; Wen S; Shen B
Ann Transl Med; 2022 Jun; 10(11):641. PubMed ID: 35813347
[TBL] [Abstract][Full Text] [Related]
7. [Retrospective study on the efficacy and safety of low dose apatinib in reversing chemotherapy resistance in sarcoma].
Ye T; Yuan SY; Fan L; Feng LW; Chen YT; Chen J
Zhonghua Yi Xue Za Zhi; 2022 Aug; 102(31):2435-2440. PubMed ID: 36000372
[No Abstract] [Full Text] [Related]
8. Phase II clinical trial using camrelizumab combined with apatinib and chemotherapy as the first-line treatment of advanced esophageal squamous cell carcinoma.
Zhang B; Qi L; Wang X; Xu J; Liu Y; Mu L; Wang X; Bai L; Huang J
Cancer Commun (Lond); 2020 Dec; 40(12):711-720. PubMed ID: 33314747
[TBL] [Abstract][Full Text] [Related]
9. The Efficacy and Safety of Apatinib in Advanced Synovial Sarcoma: A Case Series of Twenty-One Patients in One Single Institution.
Wang Y; Lu M; Zhou Y; Zhou S; Yu X; Tang F; Luo Y; Zhang W; Duan H; Min L; Tu C
Cancer Manag Res; 2020; 12():5255-5264. PubMed ID: 32669874
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of apatinib in patients with advanced gastric or gastroesophageal junction adenocarcinoma after the failure of two or more lines of chemotherapy (AHEAD): a prospective, single-arm, multicenter, phase IV study.
Li J; Qin S; Wen L; Wang J; Deng W; Guo W; Jia T; Jiang D; Zhang G; He Y; Ba Y; Zhong H; Wang L; Lin X; Yang J; Zhao J; Bai Y; Wu X; Gao F; Sun G; Wu Y; Ye F; Wang Q; Xie Z; Yi T; Huang Y; Yu G; Lu L; Yuan Y; Li W; Liu L; Sun Y; Sun Y; Yin L; Hou Z
BMC Med; 2023 May; 21(1):173. PubMed ID: 37147645
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Apatinib Treatment for Advanced Cholangiocarcinoma After Failed Gemcitabine-Based Chemotherapy: An Open-Label Phase II Prospective Study.
Zhang G; Gong S; Pang L; Hou L; He W
Front Oncol; 2021; 11():659217. PubMed ID: 34012920
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of apatinib in patients with advanced nonsmall cell lung cancer that failed prior chemotherapy or EGFR-TKIs: A pooled analysis.
Ma JT; Sun J; Sun L; Zhang SL; Huang LT; Han CB
Medicine (Baltimore); 2018 Aug; 97(35):e12083. PubMed ID: 30170427
[TBL] [Abstract][Full Text] [Related]
13. Clinical study of apatinib in the treatment of stage IV osteogenic sarcoma after failure of chemotherapy.
Liao Z; Li T; Zhang C; Liu X; Xing R; Teng S; Yang Y; Zhao G; Bai X; Zhao J; Yang J
Cancer Biol Med; 2020 May; 17(2):501-512. PubMed ID: 32587785
[No Abstract] [Full Text] [Related]
14. Efficacy and safety of apatinib plus docetaxel as the second or above line treatment in advanced nonsquamous NSCLC: A multi center prospective study.
Jiang Q; Zhang NL; Ma DY; Tan BX; Hu X; Fang XD
Medicine (Baltimore); 2019 Jun; 98(26):e16065. PubMed ID: 31261514
[TBL] [Abstract][Full Text] [Related]
15. The efficacies and biomarker investigations of antiangiogenic agents and PD-1 inhibitors for metastatic soft tissue sarcoma: A multicenter retrospective study.
Liu Z; Wang X; Wang J; Zhang P; Li C; Wang B; Gao S; Liu O; Yao W
Front Oncol; 2023; 13():1124517. PubMed ID: 36910639
[TBL] [Abstract][Full Text] [Related]
16. Apatinib combined with paclitaxel-based chemotherapy in patients with taxane-resistant advanced gastric cancer: a single-arm exploratory study.
Zhao S; Fan N; Li H; Liu J; Huang F; Chen Y; Zhou M; Yu J; Lin R
Ann Transl Med; 2020 Oct; 8(19):1233. PubMed ID: 33178765
[TBL] [Abstract][Full Text] [Related]
17. Apatinib for patients with metastatic biliary tract carcinoma refractory to standard chemotherapy: results from an investigator-initiated, open-label, single-arm, exploratory phase II study.
Wang C; Huang M; Geng Q; Li W; Chang J; Tang W; Guo W
Ther Adv Med Oncol; 2021; 13():17588359211039047. PubMed ID: 34484431
[TBL] [Abstract][Full Text] [Related]
18. The efficacy and safety of apatinib in metastatic alveolar soft part sarcoma: a case series of six patients in one institution.
Wang Y; Min L; Zhou Y; Tang F; Luo Y; Zhang W; Duan H; Tu C
Cancer Manag Res; 2019; 11():3583-3591. PubMed ID: 31118781
[No Abstract] [Full Text] [Related]
19. Efficacy and safety of apatinib in advanced sarcoma: an open-label, nonrandomized, single-center study of 45 patients.
Weitao Y; Fangxing W; Qiqing C; Jiaqiang W
Anticancer Drugs; 2019 Aug; 30(7):e0778. PubMed ID: 31305297
[TBL] [Abstract][Full Text] [Related]
20. Multicenter phase II study of apatinib in non-triple-negative metastatic breast cancer.
Hu X; Cao J; Hu W; Wu C; Pan Y; Cai L; Tong Z; Wang S; Li J; Wang Z; Wang B; Chen X; Yu H
BMC Cancer; 2014 Nov; 14():820. PubMed ID: 25376790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
